• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

NeuroSense Therapeutics Terminates At-The-Market Equity Offering Program


The company announced that it is fully funded beyond clinical Phase IIb ALS results.

NeuroSense Therapetucis announced that it is fully funded into the second quarter of 2024.

In a press release, the company also revealed that it is ending its at-the-market (ATM) offering program. The program will officially close on Oct. 4.

"Having completed enrollment in our Phase IIb ALS trial in the second quarter, we continue to dose and monitor patients for the six-month double blind portion of the study. We also expect to enroll our first patient in our new Phase II Alzheimer's disease study in the coming weeks. With clarity on our R&D and operating expenses, we are confident that our Company is fully funded into the second quarter of 2024," NeuroSense Founder and CEO, Alon Ben-Noon, said in a press release.

"With our extensive use of biomarkers in the Phase IIb study, we are optimistic about PrimeC's mechanism of action and its corresponding clinical results anticipated in Q4 2023,” he continued.

NeuroSense is developing treatments for severe neurodegenerative diseases.


(Oct. 2, 2023); NeuroSense; NeuroSense Ends Its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results; https://www.prnewswire.com/news-releases/neurosense-ends-its-at-the-market-equity-offering-program-company-is-fully-funded-beyond-clinical-phase-2b-als-results-301944405.html

Related Videos
Related Content